CORRECTION Open Access



Correction to: CD90^{low} glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells

Bing-zhou Xue^{1†}, Wei Xiang^{1†}, Qing Zhang^{1,2}, Hao-fei Wang¹, Yu-jie Zhou¹, Han Tian¹, Ahmed Abdelmaksou^{1,3}, Jian Xue⁴, Min-xuan Sun⁵, Dong-ye Yi¹, Nan-xiang Xiong¹, Xiao-bing Jiang¹, Hong-yang Zhao¹ and Peng Fu^{1*}

Correction to: Stem Cell Research & Therapy (2021) 12:394 https://doi.org/10.1186/s13287-021-02458-

The original article [1] contained an error in Fig. 3B which was given wrong marking figures of NC.U87(0h) and KD.U87(0h).

The original figures and data of Fig. 3 were checked by the authors and the editors of this article, no more figure or data was changed.

The corrected Fig. 3 is presented ahead.

Author details

¹Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. ²Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China. ³Department of Neurosurgery, Faculty of Medicine, Helwan University, Cairo 11435, Egypt. ⁴Henan Vocational University of Science and Technology, Zhoukou 466000, China. ⁵Jiangsu Key Lab of Medical Optics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China.

The original article can be found online at https://doi.org/10.1186/s13287-021-02458-8.

¹ Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Full list of author information is available at the end of the article



Published online: 06 September 2021

© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: pfu@hust.edu.cn

[†]Bing-zhou Xue and Wei Xiang contributed equally to this work

Xue et al. Stem Cell Res Ther (2021) 12:493 Page 2 of 2




Fig. 3 FOXS1 overexpression induces TMZ resistance in glioma cells. The proliferation (**A**), wound-healing (**B**) and apoptosis assay (**C**) of glioma cells with different FOXS1 expression under 200 μ M TMZ treatment. control, normal control; NC, negative control; KD, knockdown; OE, overexpression ($n \ge 3$, *P < 0.05, ***P < 0.001)

Reference

 Bing-zhou X, et al. CD90^{low} glioma-associated mesenchymal stromal/ stem cells promote temozolomide resistance by activating FOXS1mediated epithelial-mesenchymal transition in glioma cells. Stem Cell Res Ther. 2021;12:394. https://doi.org/10.1186/s13287-021-02458-8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

